Overall, Trimel Pharmaceuticals' focused approach to addressing niche medical conditions coupled with its success in advancing various products through clinical trials signifies its potential for growth and impact within the Biotechnology and Health Care industries. The recent investment is indicative of the investor confidence in Trimel Pharmaceuticals' innovative solutions and its potential to address unmet medical needs. As the company continues to advance its product pipeline, it presents an intriguing opportunity for venture capital firms seeking to invest in pharmaceutical ventures with a vision for addressing underrepresented medical conditions.
Trimel Pharmaceuticals
Pioneering innovative solutions for male hypogonadism, female sexual dysfunction, and respiratory disorders since 2008.
Founded 2008
Post-IPO Equity
Total: $72.45M
Biotechnology, Health Care
General Information
Company Name
Trimel Pharmaceuticals
Founded Year
2008
Industries
Biotechnology, Health Care
Funding Stage
Post-IPO Equity
Social
BounceWatch is an independent company data service, not affiliated with Trimel Pharmaceuticals. To contact Trimel Pharmaceuticals, visit trimelpharmaceuticals.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Trimel Pharmaceuticals compare?
A PDF of Trimel Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Trimel Pharmaceuticals soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
From the desk
Is Trimel Pharmaceuticals on your competitive set?
Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.
Book a 7-day ReadoutDiscover More
Biotechnology
About Trimel Pharmaceuticals
Business keywords: Pharmaceuticals, Specialty Pharmaceuticals, Drug Development, Clinical Trials, Testosterone Therapy, Respiratory Disorders, Intranasal Gel Formulation, Dopamine Treatment, Parkinson's Disease, Asthma Treatment, Male Hypogonadism, Female Sexual Dysfunction, Innovation, Medical Research, Canada
Funding Rounds & Investors (6)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post IPO Equity | $4.53M | - |
|
29 Mar 2019 |
| Post IPO Equity | $2.00M | - |
|
05 May 2016 |
| Post IPO Equity | $2.13M | - |
|
14 Aug 2014 |
| Post IPO Equity | $10.54M | 2 |
|
19 Feb 2014 |
| Post IPO Equity | $40.00M | - |
|
20 Mar 2013 |
| Post IPO Equity | $13.25M | - |
|
28 Jun 2012 |
Trimel Pharmaceuticals Alternatives & Competitors
Trimel Pharmaceuticals vs
Pioneering advancements in female sexual health, menopause, contraception, and male hypogonadism wit...
Post-IPO Equity
Biotechnology, Health Care
FAQ About Trimel Pharmaceuticals
Pioneering innovative solutions for male hypogonadism, female sexual dysfunction, and respiratory disorders since 2008.
Trimel Pharmaceuticals was founded in 2008.
Trimel Pharmaceuticals operates in Biotechnology and Health Care. Its work centres on Pharmaceuticals, Specialty Pharmaceuticals, Drug Development and Clinical Trials.
Trimel Pharmaceuticals has completed 6 funding rounds, raising a total of $72.45M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Trimel Pharmaceuticals include BioSante Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trimel Pharmaceuticals and BioSante Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Trimel Pharmaceuticals, https://bouncewatch.com/company/trimel-pharmaceuticals, updated 12 September 2024. When citing, please name BounceWatch and link this page.
